Cargando…
Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
BACKGROUND: In this study, we aimed to compare the intensive care unit (ICU) admission rate of hospitalized mild/moderate COVID-19 patients treated with hydroxychloroquine (HCQ), favipiravir, and HCQ plus favipiravir. METHODS: Single center retrospective designed observational study conducted in Ank...
Autores principales: | Guner, Rahmet, Hasanoglu, Imran, Kayaaslan, Bircan, Aypak, Adalet, Akinci, Esragul, Bodur, Hurrem, Eser, Fatma, Kaya Kalem, Ayse, Kucuksahin, Orhan, Ates, Ihsan, Bastug, Aliye, Tezer Tekce, Yasemin, Bilgic, Zeynep, Gursoy, Fahriye Melis, Akca, Hatice Nisa, Izdes, Seval, Erdem, Deniz, Asfuroglu, Emra, Hezer, Habibe, Kilic, Hatice, Cıvak, Musa, Aydogan, Sibel, Buzgan, Turan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771901/ https://www.ncbi.nlm.nih.gov/pubmed/33647553 http://dx.doi.org/10.1016/j.jiph.2020.12.017 |
Ejemplares similares
-
Response to the letter to the editor
por: Guner, Rahmet, et al.
Publicado: (2022) -
A useful and sensitive marker in the prediction of COVID-19 and disease severity: Thiol
por: Kalem, Ayse Kaya, et al.
Publicado: (2021) -
Azithromycin/favipiravir/hydroxychloroquine: Various toxicities: 7 case reports
Publicado: (2022) -
Azithromycin/favipiravir/hydroxychloroquine: Hypoglycaemia and off label use: case report
Publicado: (2021) -
Interaction between favipiravir and hydroxychloroquine and their combined drug assessment: in silico investigations
por: Parlak, Cemal, et al.
Publicado: (2021)